In addition, genes with unknown roles in SLE pathophysiology have been identified. These findings may provide new routes towards improved clinical management of this complex disease. You have full ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Both TYK2 and types I and III interferon are involved in CLE pathophysiology. In a phase II trial of patients with SLE and baseline CLASI-A score ≥10, patients treated with any of three doses of ...

shedding new light on SLE pathophysiology. This finding holds potential as a biomarker reflecting disease activity. REFERENCES: [1] Ota, M. et al. Dynamic landscape of immune cell-specific gene ...

Diabetes: a review of its pathophysiology, and advanced methods of mitigation ... miRNA-mediated control of B cell responses in immunity and SLE. Front Immunol. 2021. Vol. 12:683710 Mostahfezian M, ...

We aimed to investigate stress effects on the neuropsychiatric pathophysiology in SLE using lupus-prone mice and patients’ data. Methods Sleep disturbance stress (SDS) for 2 weeks was placed on ...

Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...

Early initiation of hydroxychloroquine (HCQ) in patients with cutaneous lupus erythematosus (CLE) reduces the risk for progression to systemic lupus erythematosus (SLE) by 87% over time.